



*The Medical **Bulletin***

In Cardiology

With the recent publication of new clinical trials in the management of heart failure, practice guidelines are rapidly changing. Although beta-blockers and MRA were already well established in reducing morbidity and mortality, newer studies have shown that ARNI are superior to ACE inhibitors (PARADIGM 2014, PIONEER-HF 2019). SGLT2 inhibitors have also proven to decrease heart failure hospitalization and cardiovascular deaths (DAPA-HF 2019, EMPEROR-Reduced 2020).

This has led to the publication of the 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure.

***Dr. Sangram S. Birada
MD, FICP, FACP, FRCP***